BMI View: We forecast growth in Spain's pharmaceutical market will slow in 2018. Despite the growing
demand for innovative drugs being driven an ageing population, patented drugmakers' revenue generating
opportunities will remain limited. We expect the government to remain committed to fiscal consolidation,
targeting the healthcare sector and prescription drug expenditure in particular, as it faces considerable
pressure from rising healthcare costs.